![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
ITI will employ CoImmune’s process for manufacturing and cGMP work for the advancement of ITI-1020, ITI’s autologous dendritic cell (DC) investigational vaccine loading with mRNA encoding LAMP: pp65 for the treatment of newly diagnosed glioblastoma (GBM).
Lead Product(s): ITI-1020
Therapeutic Area: Oncology Product Name: ITI-1020
Highest Development Status: N/A Product Type: Vaccine
Partner/Sponsor/Collaborator: Immunomic Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 19, 2020
Details:
CoImmune will use the proceeds from the financing to fund its ongoing Phase 2b trial for lead asset, CMN-001, in advanced renal cell carcinoma and multiple Phase 1-2a trials with its newly acquired technology, CAR-CIK, in five leukemia and lymphoma settings.
Lead Product(s): CMN-001
Therapeutic Area: Oncology Product Name: CMN-001
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: FIDIM Group
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 10, 2020